Contact
searchSearch
HMP Global

July 2012 - FRMC

Tamoxifen Therapy for 10 Years versus 5 Years
07/22/2013
Tim Casey
  Chicago—Patients who took tamoxifen for 10 years had a reduced disease recurrence and breast cancer mortality compared with a group receiving the drug for 5 years, according to a randomized, phase 3 trial that began >20 years ago. The...
  Chicago—Patients who took tamoxifen for 10 years had a reduced disease recurrence and breast cancer mortality compared with a group receiving the drug for 5 years, according to a randomized, phase 3 trial that began >20 years ago. The...
  Chicago—Patients who took...
07/22/2013
First Report Managed Care
Novel Monoclonal Antibody to PCSK9
07/23/2012
Kevin L. Carter
Studies of animal models have found that proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases, has a role in the post-translational regulation of LDL-receptor activity. PCSK9, which is synthesized primarily in the...
Studies of animal models have found that proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases, has a role in the post-translational regulation of LDL-receptor activity. PCSK9, which is synthesized primarily in the...
Studies of animal models have...
07/23/2012
First Report Managed Care
Bosutinib versus Imatinib in Treating Chronic Myeloid Leukemia
07/23/2012
Tim Casey
Chicago—After 30 months, patients with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia who took bosutinib had superior efficacy and safety results compared with those who received imatinib, according to updated...
Chicago—After 30 months, patients with Philadelphia chromosome-positive chronic phase chronic myeloid leukemia who took bosutinib had superior efficacy and safety results compared with those who received imatinib, according to updated...
Chicago—After 30 months,...
07/23/2012
First Report Managed Care
Continuous Therapy in Prostate Cancer Patients
07/23/2012
Tim Casey
Chicago—A phase 3, international, randomized trial of patients with hormone-sensitive metastatic prostate cancer found that overall survival was inferior in those who had intermittent androgen deprivation therapy compared with those who...
Chicago—A phase 3, international, randomized trial of patients with hormone-sensitive metastatic prostate cancer found that overall survival was inferior in those who had intermittent androgen deprivation therapy compared with those who...
Chicago—A phase 3,...
07/23/2012
First Report Managed Care
Orteronel to Treat Nonmetastatic Castration-Resistant Prostate Cancer
07/23/2012
Tim Casey
Chicago—An analysis of an ongoing phase 2 study found that patients with nonmetastatic, castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA) reacted well to and managed toxicities when taking orteronel, an...
Chicago—An analysis of an ongoing phase 2 study found that patients with nonmetastatic, castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA) reacted well to and managed toxicities when taking orteronel, an...
Chicago—An analysis of an...
07/23/2012
First Report Managed Care
T-DM1 Superior to Capecitabine plus Lapatinib in Advanced Breast Cancer
07/23/2012
Tim Casey
Chicago—The first phase 3 study to evaluate trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer found that the investigational antibody drug conjugate had superior efficacy and safety compared with an...
Chicago—The first phase 3 study to evaluate trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer found that the investigational antibody drug conjugate had superior efficacy and safety compared with an...
Chicago—The first phase 3 study...
07/23/2012
First Report Managed Care
Nab-Paclitaxel, Ixabepilone Not Superior to Paclitaxel
07/23/2012
Tim Casey
Chicago—A phase 3 study found that nab-paclitaxel and ixabepilone were not superior to standard treatment (paclitaxel) in patients with chemotherapy-naïve metastatic breast cancer who also received bevacizumab. Hope S. Rugo, MD, professor of...
Chicago—A phase 3 study found that nab-paclitaxel and ixabepilone were not superior to standard treatment (paclitaxel) in patients with chemotherapy-naïve metastatic breast cancer who also received bevacizumab. Hope S. Rugo, MD, professor of...
Chicago—A phase 3 study found...
07/23/2012
First Report Managed Care
Afatinib Effective in Treating Late-Stage NSCLC
07/23/2012
Tim Casey
Chicago—Patients with advanced stage non–small cell lung cancer (NSCLC) who took the investigational oral agent afatinib had a significantly longer progression-free survival compared with those who received a standard combination chemotherapy...
Chicago—Patients with advanced stage non–small cell lung cancer (NSCLC) who took the investigational oral agent afatinib had a significantly longer progression-free survival compared with those who received a standard combination chemotherapy...
Chicago—Patients with advanced...
07/23/2012
First Report Managed Care
Nausea and Vomiting in Cancer Patients
07/23/2012
Tim Casey
Orlando—When cancer patients undergo chemotherapy treatments, they face numerous challenges, among them nausea and vomiting. Physicians and nurses sometimes underestimate how many patients will have these side effects, according to Charles...
Orlando—When cancer patients undergo chemotherapy treatments, they face numerous challenges, among them nausea and vomiting. Physicians and nurses sometimes underestimate how many patients will have these side effects, according to Charles...
Orlando—When cancer patients...
07/23/2012
First Report Managed Care

News

News
Integrated Genetic Profiling in Acute Myeloid Leukemia
07/23/2012
Kevin L. Carter
A series of somatic mutations that affect the progression and development of acute myeloid leukemia (AML) has recently been discovered. The prognostic relevance of cytogenetic abnormalities has led to the widespread adoption of risk...
A series of somatic mutations that affect the progression and development of acute myeloid leukemia (AML) has recently been discovered. The prognostic relevance of cytogenetic abnormalities has led to the widespread adoption of risk...
A series of somatic mutations...
07/23/2012
First Report Managed Care

Behind the Bill

Behind the Bill
SCOTUS Takes on the Nondelegation Doctrine: Surprising Reactions and What They Mean for Agency Power
04/02/2025
Katie Hayes, MJ
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard arguments in Federal Communication Commission (FCC) v Consumers’ Research, a case that I covered in February and one that could dramatically reshape federal agency authority through the nondelegation...
The Supreme Court recently heard...
04/02/2025
First Report Managed Care
Behind the Bill
Dr Oz’s Prescription for Making Medicaid “Viable at Every Level”
03/26/2025
Katie Hayes, MJ
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the Senate Finance Committee voted to advance Dr Mehmet Oz in his confirmation as the next head of the Centers for Medicare and Medicaid Services (CMS).1 The full Senate vote is expected “soon” (whatever that...
On Tuesday, March 25, 2025, the...
03/26/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question Continues: Dr Oz's Confirmation and the Future of Medicaid
03/19/2025
Katie Hayes, MJ
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880 billion question facing Congress—whether lawmakers could achieve their budget goals without cutting Medicaid. This week, that question took center stage as Dr Mehmet Oz, President Trump's nominee to lead the...
Last week, I explored the $880...
03/19/2025
First Report Managed Care
Behind the Bill
The $880 Billion Question: Can Congress Cut Spending Without Touching Medicaid?
03/12/2025
Katie Hayes, MJ
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from administrative law for a moment to provide a quick update on Medicaid. With news coming from all sides, what does the future of Medicaid actually look like? The House of Representatives narrowly passed a budget...
I’d like to step away from...
03/12/2025
First Report Managed Care
Behind the Bill
RFK Jr’s Public Comment Ban: The Silent Shift in Health Care Rulemaking
03/05/2025
Katie Hayes, MJ
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative law continues, and with it, the dismantling of decades-long precedent. In June, the Supreme Court overturned a 40-year-old doctrine that allowed federal agencies to interpret their own ambiguous statutes. Later...
The erosion of administrative...
03/05/2025
First Report Managed Care
Behind the Bill
Prevention Over Pills? The First 2 Weeks of Health Care’s New Direction
02/26/2025
Katie Hayes, MJ
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from Robert F Kennedy Jr’s confirmation as Secretary of Health and Human Services (HHS), but the changes are already coming fast and furious—a key theme of the Trump Administration’s actions within the last several...
The dust has barely settled from...
02/26/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 2)
02/19/2025
Katie Hayes, MJ
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the potential revival of the nondelegation doctrine through Federal Communication Commission v Consumers’ Research. Today, I want to examine what this could mean for health care regulation by considering the parallels...
Last week, I explored the...
02/19/2025
First Report Managed Care
Behind the Bill
The Nondelegation Doctrine: The Next Constitutional Showdown (Part 1)
02/12/2025
Katie Hayes, MJ
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust had settled from the Chevron decision, the Supreme Court is gearing up to hear arguments in Federal Communications Commission v Consumers' Research next month, potentially reviving the long-dormant nondelegation...
Just when you thought the dust...
02/12/2025
First Report Managed Care
Behind the Bill
No, President Trump Did Not Actually Sign an Executive Order That Would Increase Drug Costs for Beneficiaries
02/05/2025
Katie Hayes, MJ
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President Trump issued an executive order rescinding several Biden-era health care initiatives, including 3 experimental drug pricing models developed by the Center for Medicare and Medicaid Innovation (CMMI). Oh boy did...
On inauguration day, President...
02/05/2025
First Report Managed Care
Behind the Bill
Robert F. Kennedy Jr’s Confirmation and the Unexpected Turn in the Drug Pricing Debate
01/29/2025
Katie Hayes, MJ
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug Pricing Drama Just when you thought the drug pricing debate couldn't get more interesting, Robert F. Kennedy Jr adds an unexpected twist. During closed-door Senate meetings, President Trump’s US Department of...
The Plot Thickens in Drug...
01/29/2025
First Report Managed Care

Subscribe and Stay Ahead With Daily Industry Insights

First Report Managed Care Newsletter

Trending Articles

Elizabeth Brem University of California Irvine
Videos
Analyzing Patient Selection and the Utility of CNS Prophylaxis for Patients With DLBCL
04/20/2023
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.
In a debate at the 2023 Great Debates & Updates in Hematologic Malignancies conference in New York, New York, Elizabeth A. Brem, MD, analyzed the role of central nervous system prophylaxis for patients with DLBCL.
In a debate at the 2023 Great...
04/20/2023
Oncology
News
Thousands Face Medicaid Coverage Disruptions in South Dakota and North Carolina
05/18/2023
Arielle Zionts
Now that the public health emergency has expired, individuals may lose coverage but then requalify several months later in states which have recently approved Medicaid expansion.
Now that the public health emergency has expired, individuals may lose coverage but then requalify several months later in states which have recently approved Medicaid expansion.
Now that the public health...
05/18/2023
First Report Managed Care
News
Digital Therapeutics "Viable Solution" for Mental Health Needs
06/07/2023
Jolynn Tumolo
“The participants were willing to utilize digital therapeutics if available, and even preferred this type of support compared to actually visiting a clinic,” researchers wrote.
“The participants were willing to utilize digital therapeutics if available, and even preferred this type of support compared to actually visiting a clinic,” researchers wrote.
“The participants were willing...
06/07/2023
First Report Managed Care
News
First Gene Therapy for Severe Hemophilia A Is Approved
06/29/2023
Amanda Balbi
This approval comes after a safety and effectiveness trial showed that the treatment improved participants’ annualized bleeding rate after 3 years.
This approval comes after a safety and effectiveness trial showed that the treatment improved participants’ annualized bleeding rate after 3 years.
This approval comes after a...
06/29/2023
First Report Managed Care
Stock image of a doctor holding a phone
Commentary
Prescription Digital Therapeutics: Ongoing Efforts to Expand Awareness, Integrate Into Clinical Practice
07/28/2023
Yvette C. Terrie, BS Pharm, RPh
Yvette Terrie shares digital therapeutic updates regarding FDA approvals, recent and upcoming clinical trials, and current industry regulations.
Yvette Terrie shares digital therapeutic updates regarding FDA approvals, recent and upcoming clinical trials, and current industry regulations.
Yvette Terrie shares digital...
07/28/2023
First Report Managed Care

July 2012 Volume 9 Issue 7

View Issue Archive
Editorial Correspondence

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use